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Introduction: The impact of incomplete lung cancer
resection on survival has never been systematically quan-
tiﬁed, nor has the value of postoperative adjuvant therapy
in this setting been determined.
Methods: We evaluated lung cancer resections in the Na-
tional Cancer Data Base from 2004 to 2011 to identify
factors associated with margin involvement. We compared
the survival of patients with and without positive margins
and evaluated the impact of postoperative adjuvant
therapy.
Results: Of 112,998 resections performed during the 8
years, 5,335 (4.7%) had positive margins. Patient de-
mographic and clinical factors associated with an
increased adjusted OR of incomplete resection included
black race (p ¼ 0.006), age-based Medicare insurance
(p ¼ 0.006), urban residence (p ¼ 0.01), histologic
diagnosis of squamous cell carcinoma, high tumor grade,
tumor overlapping more than one lobe, and advanced
pathologic stage (p < 0.001 for all clinical factors).
Community cancer programs (p ¼ 0.002), institutions
with high proportions of underinsured patients (p ¼
0.01), and institutions with a lower volume of cancer
resections (p ¼ 0.006) also had an increased adjusted
OR. The crude 5-year survival rates of patients with
complete versus incomplete resections were 58.5%
versus 33.8% (log-rank p < 0.001). After an incomplete
resection, adjuvant chemotherapy was associated with
improved 5-year survival across all stages (p < 0.01);
radiotherapy was associated with worse survival in pa-
tients with stage I disease (p < 0.001).
Conclusions: Margin involvement signiﬁcantly impaired
survival after lung cancer resection irrespective of stage.
Causative institutional and provider practices shouldbe identiﬁed to minimize this adverse outcome. Post-
operative adjuvant chemotherapy mitigated mortality risk
independently of stage, whereas postoperative radiotherapy
exacerbated the risk in patients with stage I disease. These
ﬁndings need validation in prospective trials.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: Non–small cell; Positive margins; Quality of care;
Outcomes; Surgical resection; SurvivalIntroduction
Lung cancer is the oncologic scourge of the present
age, causing 160,000 deaths in the United States annu-
ally and accounting for 28% of all cancer mortality in the
United States.1 Only 17% of all patients diagnosed with
lung cancer survive up to 5 years.1 The overwhelming
majority of long-term survivors have had surgery as a
component of their treatment; however, most patients
who undergo surgery for lung cancer die within 5 years.2
Improving surgical outcomes is therefore a viableJournal of Thoracic Oncology Vol. 11 No. 1: e5-e16
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survival.
Attaining the beneﬁt of surgical resection of non–
small cell lung cancer requires complete (R0) resection
of all evident disease.3 In relation to lung cancer, how-
ever, the term complete resection has been ill-deﬁned,
with ongoing controversy about the optimal extent of
resection of the lung parenchyma4 and nodal examina-
tion.5–9 Even the prognostic implication of a positive
resection margin has been questioned.5,6,10 Current
practice guidelines recognize that patients with micro-
scopic (R1) or macroscopic (R2) positive resection
margins are at high risk for death3; however, this risk
has never been systematically quantiﬁed.11
Practice guidelines recommend re-resection as the
preferred response to margin positivity for patients with
stage I and II disease; however, it is infeasible in many
cases, and surgeons are often reluctant to subject pa-
tients to re-resection in any case.3 Alternative options to
surgery are postoperative adjuvant radiation therapy,
chemotherapy, and the combination of modalities in
certain situations.3,11 However, postoperative radio-
therapy increases the risk for mortality in patients with
completely resected pathologic N0 or N1 non–small cell
lung cancer.12 The beneﬁt of radiotherapy has never
been clearly demonstrated in patients with positive
margins.11 The role of chemotherapy in managing pa-
tients with positive margins is even less well deﬁned
because clinical trials of adjuvant chemotherapy typi-
cally exclude patients with positive resection mar-
gins.13,14 Practice guidelines in this area rely
predominantly on expert opinion,3,5 contradictory
single-institution reports,10,15–22 ad hoc secondary anal-
yses of patient subsets in clinical trials designed to
answer other questions,6 or literature reviews.11
We analyzed the U.S. National Cancer Data Base
(NCDB) to establish the proportion of non-R0 resections
in a contemporary multiyear national cohort. We also
sought to identify factors associated with resection
margin positivity, deﬁnitively quantify the survival im-
plications of resection with positive margins, and
examine the impact of nonsurgical adjuvant therapies on
survival.Materials and methods
Data sources
The NCDB, which is sponsored jointly by the Amer-
ican College of Surgeons and the American Cancer Soci-
ety, is a clinical oncology database sourced from hospital
registry data that are collected in more than 1500
Commission on Cancer–accredited facilities. Data in
the NCDB are used to analyze and track patients with
malignant neoplastic diseases, their treatments, andoutcomes. The data represent approximately 70% of
newly diagnosed cancer cases in the United States.23
This study was exempted from the informed consent
requirement because it analyzes a preexisting, de-
identiﬁed data set.Study subjects
We selected patients aged 18 to 90 years who had a
ﬁrst diagnosis of primary non–small cell lung cancer
(International Classiﬁcation of Disease for Oncology, Ninth
Revision, Clinical Modiﬁcation [ICD-9-CM] site codes
C34.0–C34.9), pathologic stage I through stage IIIA, that
was established from 2004 to 2011 and who underwent
cancer-directed surgery in a Commission on Cancer–
accredited reporting facility within 6 months of
diagnosis (Fig. 1). We excluded patients with missing
information on gender, administration of radiation
therapy, or administration of chemotherapy and those
with metastatic disease, unmeasurable tumor, no last
contact information, or unknown margin status. Because
we were interested in the quality of oncologic resection,
we excluded patients who died within 60 days after
their operation.Study outcomes and covariates
The primary outcome was margin status (positive or
negative) identiﬁed from the ﬁnal status of the surgical
margins after resection of the primary tumor. Positive
margin was deﬁned if residual tumor (R1, R2, or not
otherwise speciﬁed) was recorded in the pathology
report. Secondary outcomes were overall survival rates
at 1, 3, and 5 years in patients categorized by margin
status. Patients were censored if they were lost to
follow-up or still alive at the end of the study period.
We examined associations between margin status
and patient-level clinical and demographic covariates, as
well as institutional covariates. Patient-level de-
mographic covariates included age, sex, race, insurance
status, U.S. census region of residence, residence in a
rural or urban location, median income level in patients’
neighborhood of residence, year of cancer diagnosis and
comorbidities. Patient-level clinical covariates included
disease characteristics such as tumor histologic features,
grade, size, T category, N category, aggregate American
Joint Committee on Cancer (AJCC) pathologic stage, and
the treatment characteristics extent of resection and
lymph node examination results. Institutional covariates
included facility type, facility location by census division,
proportion of the institution’s patients with no insurance
or insured by Medicaid (in quartiles), volume of lung
cancer operations as a proportion of the institution’s
entire volume of cancer operations (in quartiles), and
total annual volume of cancer operations (in quartiles).
Exclusions: paƟents with
missing informaƟon on 
gender (n=33)
radiaƟon therapy administraƟon (n=1529)
chemotherapy administraƟon (n=1570)
metastaƟc disease (n=103)
unmeasurable tumor (n=4)
no last contact informaƟon (n=266)
unknown surgical margin status (n=1036)
death within 60 days of surgery (n=7660)
missing facility locaƟon (n=2)
PaƟents, aged 18-90, diagnosed during 2004-2011 with first primary invasive malignant non-small 
cell* lung cancer and underwent cancer-directed surgery† within six months of diagnosis in the 
NaƟonal Cancer Data Base (n=125,201)
AnalyƟc study populaƟon (n = 112,998)
Figure 1. Patient selection scheme. *The histologic diagnosis of non–small cell lung cancer was identiﬁed through the
following International Classiﬁcation of Diseases for Oncology, Third Edition (ICD-O-3) histologic diagnosis codes: 8010–8040,
8050–8076, 8140, 8143, 8211, 8230–8231, 8246, 8250–8260, 8310, 8320, 8323, 8430, 8470–8490, 8550–8573, 8980, and 8981.
†Cancer-directed surgery was identiﬁed through site-speciﬁc surgical codes (21, 22, 30–70), including those for sublobectomy,
lobectomy, bilobectomy, and pneumonectomy.
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between use of preoperative adjuvant therapy and
margin positivity. We also examined survival after
postoperative adjuvant therapy in groups of patients
stratiﬁed by stage. Adjuvant therapy, including chemo-
therapy, radiotherapy, or both, was identiﬁed if
commenced within 6 months before or after surgery.
Chemotherapy was identiﬁed if administered as a single
agent or multiple agents. Radiotherapy was identiﬁed if
administered at the reporting facility or elsewhere.
Statistical analysis plan
Descriptive analyses were conducted to summarize
patient and institutional characteristics. Chi-square tests
were used to determine the signiﬁcance of differences
according to margin status. The yearly trend in the inci-
dence of surgical resection with positive margins was
evaluated using the Cochran-Armitage test. Univariate
and multivariate logistic regression analyses were con-
ducted to evaluate associations between patient and
institutional characteristics and positive margins. The
multivariate model included the aggregate pathologic
stage, and because it is based on the pathological T, N, and
M categories, we did not adjust separately for T, N, or M
stage to avoid problems with multicollinearity. The re-
sults of multivariate logistic regression adjusting either
aggregate pathologic stage or T, N, and M categories weresimilar; therefore, we presented results with aggregate
pathologic stage in the model.
In addition, to determine whether use of preoperative
adjuvant therapy might be associated with positive
margin, three multivariate logistic regression analyses
were performed for patients who received preoperative
chemotherapy, radiotherapy, or chemoradiation versus
those who did not receive preoperative adjuvant therapy.
To examine the impact of a resection with positive
margins on survival, 5-year overall survival distributions
in patients stratiﬁed by margin status were estimated
using the Kaplan-Meier method and compared using the
log-rank test. Additional stratiﬁcation by T category, tu-
mor size, and aggregate AJCC stage was conducted to
control possible confounding. Furthermore, to assess the
impact of postoperative adjuvant therapy use on survival
in patients with a positive margin, 5-year overall survival
rates stratiﬁed by postoperative treatment and aggre-
gate AJCC stage were estimated using the Kaplan-Meier
method. Patients who received preoperative adjuvant
therapy were excluded from all analyses of the effects of
postoperative adjuvant therapy.
To evaluate the impact of including R2 and indeter-
minate cases as margin-positive, we conducted sensi-
tivity analyses by excluding patients with R2 and/or
indeterminate cases. We also analyzed the impact on our
results of excluding patients who died within 30, 60, and
Table 1. Factors associated with margin-positive resection (univariate and multivariate analysis)
Patient characteristics
and categories
Patients,
(N ¼ 112,998),
N (%)
Patients with
margin-positive
resection,
(N ¼ 5,335
[4.7%]), N (%)
p
Value
Unadjusted
OR (95% CI) p Value
Adjusted
OR (95% CI)
p
Value
Age
18–49 6,300 (5.6) 341 (5.4) <0.001 1 1
50–64 36,940 (32.7) 1,836 (5.0) 0.91 (0.81–1.03) 0.14 1 (0.88–1.13) 0.99
65–74 42,857 (37.9) 1,915 (4.5) 0.82 (0.73–0.92) <0.001 0.84 (0.72–0.99) 0.03
75–90 26,901 (23.8) 1,243 (4.6) 0.85 (0.75–0.96) 0.008 0.89 (0.76–1.05) 0.18
Gender
Male 54,806 (48.5) 2,837 (5.2) <0.001 1
Female 58,192 (51.5) 2,498 (4.3) 0.82 (0.78–0.87) <.001 1 (0.95–1.06) 0.96
Race/ethnicity
Non-Hispanic, White 88,945 (78.7) 4111 (4.6) <0.001 1 1
Hispanic 2,464 (2.2) 119 (4.8) 1.05 (0.87–1.26) 0.63 0.99 (0.81–1.2) 0.88
Black 9,354 (8.3) 531 (5.7) 1.24 (1.13–1.36) <0.001 1.15 (1.04–1.27) 0.006
Other 2,931 (2.6) 131 (4.5) 0.97 (0.81–1.15) 0.70 0.98 (0.81–1.18) 0.80
Missing 9,304 (8.2) 443 (4.8) 1.03 (0.93–1.14) 0.54 1.05 (0.94–1.16) 0.41
Year of diagnosis
2004 12,859 (11.4) 606 (4.7) 0.06 1 1
2005 13,891 (12.3) 638 (4.6) 0.97 (0.87–1.09) 0.64 1.02 (0.9–1.14) 0.78
2006 14,216 (12.6) 662 (4.7) 0.99 (0.88–1.11) 0.83 1.02 (0.91–1.15) 0.73
2007 14,117 (12.5) 618 (4.4) 0.93 (0.83–1.04) 0.19 0.99 (0.88–1.11) 0.81
2008 14,244 (12.6) 676 (4.8) 1.01 (0.9–1.13) 0.90 1.07 (0.95–1.2) 0.28
2009 14,193 (12.6) 659 (4.6) 0.99 (0.88–1.1) 0.79 1.04 (0.93–1.17) 0.48
2010 15,114 (13.4) 791 (5.2) 1.12 (1–1.25) 0.05 0.95 (0.85–1.06) 0.35
2011 14,364 (12.7) 685 (4.8) 1.01 (0.91–1.13) 0.83 0.89 (0.79–0.99) 0.04
Insurance
Uninsured 2,185 (1.9) 133 (6.1) <0.001 1.32 (1.1–1.59) 0.003 1.07 (0.88–1.3) 0.49
Medicaid 4,822 (4.3) 274 (5.7) 1.23 (1.08–1.4) 0.002 1.03 (0.9–1.18) 0.70
Younger Medicare 6,392 (5.7) 313 (4.9) 1.05 (0.93–1.19) 0.43 0.99 (0.87–1.13) 0.87
Older Medicare 58,853 (52.1) 2,723 (4.6) 0.99 (0.93–1.05) 0.73 1.16 (1.04–1.3) 0.006
Government 220 (0.2) 10 (4.6) 0.97 (0.51–1.84) 0.93 0.69 (0.36–1.33) 0.27
Private 39,028 (34.5) 1,824 (4.8) 1 1
Missing 1,498 (1.3) 58 (3.9) 0.82 (0.63–1.07) 0.15 0.86 (0.65–1.13) 0.27
Median income—quartile 2000
<$30,000 14,702 (13.0) 751 (5.1) <0.001 1.19 (1.09–1.3) <0.001 1.09 (0.98–1.21) 0.11
$30,000–$34,999 20,829 (18.4) 1,079 (5.2) 1.21 (1.12–1.31) <0.001 1.14 (1.04–1.24) 0.004
$35,000–$45,999 31,072 (27.5) 1,498 (4.8) 1.12 (1.05–1.21) 0.001 1.05 (0.98–1.14) 0.18
$46,000þ 40,252 (35.6) 1,736 (4.3) 1 1
Missing 6143 (5.4) 271 (4.4) 1.02 (0.9–1.17) 0.72 1.08 (0.89–1.31) 0.46
Rural/urban
Rural 21,159 (18.7) 1,030 (4.9) 0.20 1.03 (0.96–1.11) 0.35 0.9 (0.83–0.98) 0.01
Urban 84,715 (74.9) 3,995 (4.7) 1 1
Unknown 7,124 (6.3) 310 (4.4) 0.92 (0.82–1.04) 0.16 0.98 (0.82–1.17) 0.81
Comorbidity
0 53,437 (47.3) 2,454 (4.6) 0.11 1 1
1 40,806 (36.1) 1,993 (4.9) 1.07 (1–1.13) 0.04 1.07 (1–1.14) 0.05
2þ 18,755 (16.6) 888 (4.7) 1.03 (0.95–1.12) 0.42 1.02 (0.94–1.11) 0.63
Census region
Northeast 23,892 (21.1) 946 (4.0) <0.001 1 1
Midwest 30,404 (26.9) 1,626 (5.4) 1.37 (1.26–1.49) <0.001 1.55 (0.93–2.6) 0.10
South 44,324 (39.2) 2,038 (4.6) 1.17 (1.08–1.27) <0.001 1.17 (0.74–1.86) 0.51
West 14,250 (12.6) 718 (5.0) 1.29 (1.17–1.42) <0.001 0.98 (0.48–1.97) 0.94
Missing 128 (0.1) 7 (5.5) 1.4 (0.65–3.01) 0.39 1.45 (0.61–3.45) 0.41
(continued)
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Table 1. Continued
Patient characteristics
and categories
Patients,
(N ¼ 112,998),
N (%)
Patients with
margin-positive
resection,
(N ¼ 5,335
[4.7%]), N (%)
p
Value
Unadjusted
OR (95% CI) p Value
Adjusted
OR (95% CI)
p
Value
Histologic diagnosis
NOS 347 (0.3) 18 (5.2) <0.001 1.37 (0.85–2.2) 0.20 1.05 (0.65–1.72) 0.84
Large cell cancer 5,320 (4.7) 261 (4.9) 1.29 (1.13–1.47) <0.001 0.98 (0.86–1.13) 0.78
Squamous cell cancer 33,768 (29.9) 2,094 (6.2) 1.65 (1.56–1.75) <0.001 1.38 (1.29–1.47) <0.001
Other 5,851 (5.2) 357 (6.1) 1.62 (1.45–1.82) <0.001 1.34 (1.19–1.51) <0.001
Adenocarcinoma 67,712 (59.9) 2,605 (3.9) 1 1
Tumor grade
Well/moderately
differentiated
64,772 (57.3) 2,528 (3.9) <0.001 1 1
Poorly differentiated/
undifferentiated
42,668 (37.8) 2,557 (6.0) 1.57 (1.48–1.66) <0.001 1.14 (1.07–1.21) <0.001
Unknown 5,558 (4.9) 250 (4.5) 1.16 (1.02–1.33) 0.03 0.98 (0.85–1.13) 0.79
Tumor size
3cm 68,906 (61.0) 2,136 (3.1) <0.001 1 1
>3cm–5cm 27,971 (24.8) 1,706 (6.1) 2.03 (1.9–2.17) <0.001 1.65 (1.54–1.77) <0.001
>5cm 15,518 (13.7) 1,422 (9.2) 3.15 (2.94–3.38) <0.001 1.94 (1.79–2.1) <0.001
Unknown 603 (0.5) 71 (11.8) 4.17 (3.25–5.36) <0.001 2.47 (1.89–3.22) <0.001
Lymph node examined
Yes 10,7002 (94.7) 4,858 (4.5) <0.001 1 1
No 5,888 (5.2) 467 (7.9) 1.81 (1.64–2) <0.001 2.14 (1.9–2.41) <0.001
Unknown 108 (0.1) 10 (9.3) 2.15 (1.12–4.12) 0.02 1.77 (0.9–3.47) 0.10
Primary site
C340—Main bronchus 725 (0.6) 88 (12.1) <0.001 2.79 (2.22–3.49) <0.001 1.4 (1.1–1.78) 0.007
C341—Upper lobe 67,878 (60.1) 3,207 (4.7) 1 1
C342—Middle lobe 5,451 (4.8) 268 (4.9) 1.04 (0.92–1.19) 0.52 1.19 (1.04–1.35) 0.01
C343—Lower lobe 35,317 (31.3) 1,464 (4.2) 0.87 (0.82–0.93) <0.001 0.83 (0.78–0.89) <0.001
C348—Overlapping lesion 1,883 (1.7) 182 (9.7) 2.16 (1.84–2.52) 0.06 1.35 (1.15–1.59) <0.001
C349—Lung NOS 1,744 (1.5) 126 (7.2) 1.57 (1.31–1.89) <0.001 1.15 (0.95–1.39) 0.16
Pathologic stage
Stage I 79,614 (70.5) 1,893 (2.4) <0.001 1 1
Stage II 21,550 (19.1) 1,950 (9.1) 4.09 (3.83–4.36) <0.001 3.79 (3.53–4.07) <0.001
Stage III 11,834 (10.5) 1,492 (12.6) 5.92 (5.52–6.36) <0.001 5.77 (5.34–6.23) <0.001
TNM path T
T1 55,320 (49.0) 1,115 (2.0) <0.001 1
T2 48,028 (42.5) 2,509 (5.2) 2.68 (2.49–2.88) <0.001
T3 8,300 (7.4) 1,516 (18.3) 10.86 (10.02–11.79) <0.001
T4 667 (0.6) 146 (21.9) 13.62 (11.23–16.52) <0.001
Unknown 683 (0.6) 49 (7.2) 3.76 (2.79–5.06) <0.001
TNM path N
N0 85,272 (75.5) 2,818 (3.3) <0.001 1
N1 16,187 (14.3) 1,342 (8.3) 2.65 (2.47–2.83) <0.001
N2 9,289 (8.2) 975 (10.5) 3.43 (3.18–3.7) <0.001
NX 2,021 (1.8) 178 (8.8) 2.83 (2.41–3.31) <0.001
Unknown 229 (0.2) 22 (9.6) 3.11 (2–4.83) <0.001
Extent of resection
Sublobectomy 15,671 (13.9) 971 (6.2) <0.001 1.53 (1.43–1.65) <0.001 1.96 (1.80–2.15) <0.001
Lobectomy/bilobectomy 91,017 (80.6) 3,757 (4.1) 1 1
Pneumonectomy 6,310 (5.6) 607 (9.6) 2.47 (2.26–2.71) <0.001 0.98 (0.89–1.09) 0.71
(continued)
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Table 1. Continued
Patient characteristics
and categories
Patients,
(N ¼ 112,998),
N (%)
Patients with
margin-positive
resection,
(N ¼ 5,335
[4.7%]), N (%)
p
Value
Unadjusted
OR (95% CI) p Value
Adjusted
OR (95% CI)
p
Value
Facility Characteristics
Facility type
Community cancer program 8,248 (7.3) 497 (6.0) <0.001 1.62 (1.42–1.84) <0.001 1.34 (1.12–1.61) 0.002
Comprehensive community
cancer program
53,784 (47.6) 2,647 (4.9) 1.31 (1.18–1.44) <0.001 1.23 (1.1–1.38) <0.001
Teaching/research 27,546 (24.4) 1,187 (4.3) 1.14 (1.02–1.26) 0.02 1.06 (0.95–1.19) 0.28
National Cancer Institute
program/network
13,418 (11.9) 512 (3.8) 1 1
Other 10,002 (8.9) 492 (4.9) 1.3 (1.15–1.48) <0.001 1.23 (1.07–1.4) 0.003
Proportion of Medicaid/
uninsured patients
Q1 (low) 26,715 (23.6) 1,157 (4.3) 0.003 1 1
Q2 30,129 (26.7) 1,433 (4.8) 1.1 (1.02–1.19) 0.02 1.07 (0.98–1.16) 0.13
Q3 31,222 (27.6) 1,497 (4.8) 1.11 (1.03–1.2) 0.008 1.08 (0.99–1.18) 0.07
Q4 (high) 24,932 (22.1) 1,248 (5.0) 1.16 (1.07–1.26) <0.001 1.13 (1.03–1.24) 0.01
Lung cancer resection as a
proportion of all surgical
procedures
Q1 (low) 2,690 (2.4) 137 (5.1) <0.001 1.13 (0.95–1.35) 0.18 1.14 (0.95–1.38) 0.15
Q2 22,445 (19.9) 1,175 (5.2) 1.17 (1.08–1.25) <0.001 1.24 (1.15–1.34) <0.001
Q3 38,529 (34.1) 1,789 (4.6) 1.03 (0.96–1.09) 0.42 1.09 (1.02–1.16) 0.02
Q4 (high) 49,334 (43.7) 2,234 (4.5) 1 1
Total volume of cancer
operations
Q1 (low) 3,377 (3.0) 206 (6.1) <0.001 1.45 (1.26–1.68) <0.001 1.17 (0.95–1.43) 0.15
Q2 13,357 (11.8) 739 (5.5) 1.31 (1.21–1.42) <0.001 1.17 (1.05–1.3) 0.006
Q3 26,773 (23.7) 1,413 (5.3) 1.25 (1.17–1.33) <0.001 1.19 (1.1–1.28) <0.001
Q4 (high) 69,491 (61.5) 2,977 (4.3) 1 1
Census division
New England 6,993 (6.2) 273 (3.9) <0.001 1 1
Middle Atlantic 17,065 (15.1) 681 (4.0) 1.02 (0.89–1.18) 0.75 1.03 (0.89–1.19) 0.72
East North Central 21,333 (18.9) 1,182 (5.5) 1.44 (1.26–1.65) <0.001 0.87 (0.51–1.47) 0.59
West North Central 9,521 (8.4) 443 (4.7) 1.2 (1.03–1.4) 0.02 0.76 (0.45–1.3) 0.31
South Atlantic 26,279 (23.3) 1,124 (4.3) 1.1 (0.96–1.26) 0.17 0.88 (0.54–1.42) 0.60
East South Central 10,175 (9) 531 (5.2) 1.36 (1.17–1.57) <0.001 1.03 (0.63–1.67) 0.92
West South Central 7,583 (6.7) 385 (5.1) 1.32 (1.12–1.54) <0.001 0.98 (0.6–1.6) 0.93
Mountain 3,628 (3.2) 210 (5.8) 1.51 (1.26–1.82) <0.001 1.41 (0.69–2.9) 0.35
Paciﬁc 10,421 (9.2) 506 (4.9) 1.26 (1.08–1.46) 0.003 1.16 (0.57–2.38) 0.68
Treatment
Received radiation
No 10,1731 (90.0) 3,000 (3.0) <0.001
Yes 11,267 (10.0) 2,335 (20.7)
Received chemotherapy
No 83,513 (73.9) 2,638 (3.2) <0.001
Yes 29,485 (26.1) 2,697 (9.2)
OR, odds ratio; CI, conﬁdence interval; NOS, not otherwise speciﬁed.
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we have reported data using the 60-day exclusion win-
dow. All tests of signiﬁcance were two-sided, and p values
less than 0.05 were considered statistically signiﬁcant. All
analyses were conducted using SAS Software, Version 9.4
(SAS Institute Inc., Cary, NC).Results
Patient demographic and clinical characteristics
and likelihood of margin positivity
Our study cohort consisted of 112,998 individuals, of
whom 5,335 (4.7%) had a margin-positive resection
Table 2. Neoadjuvant therapy and the likelihood of a margin-positive resection
Total N
Margin positivity Likelihood of margin positivity
N (%) p value ORa (95% CI) p value
Preoperative radiation <0.001
Yes 590 51 (8.6) 1.59 (1.17–2.15) 0.003
No 107,660 4,896 (4.6) 1
Preoperative chemotherapy <0.001
Yes 1,640 124 (7.6) 1.19 (0.98–1.45) 0.08
No 107,660 4,896 (4.6) 1
Preoperative chemoradiation <0.001
Yes 1,653 151 (9.1) 1.17 (0.98–1.41) 0.09
No 107,660 4,896 (4.6) 1
aOdds ratio adjusted for age at diagnosis, gender, race/ethnicity, insurance, median income level, urban/rural, histologic diagnosis, tumor
grade, tumor size, primary site, T stage, N stage, type of surgical procedure, facility type, proportion of Medicaid/uninsured patients,
proportion of lung cancer operations, volume of cancer operations.
CI, conﬁdence interval.
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over the 8-year time span (2004–2011), ranging be-
tween 4.4%, in 2007 and 5.2% in 2010 (trend test p ¼
0.07). Fifty-seven percent of margin-positive cases were
R1, 4% were R2, and 39% were not speciﬁed.
Several patient-level demographic characteristics
were independently associated with higher adjusted
odds of having an incomplete resection (see Table 1).
They included black race, older patients with Medicare
insurance coverage, and residence in an urban area.
Associated patient-level clinical factors were squamous
and “other” histologic diagnosis (as opposed to adeno-
carcinoma), poor histologic differentiation, larger tu-
mors, lymph node involvement (or unknown lymph node
status), tumors that overlapped multiple lobes or were
located in the middle lobe or in the main-stem bronchus,
and advanced stage (in terms of T category, N category,
or aggregate stage). Patients with sublobar resections
were more likely to have positive margins than were
those who had a lobectomy or pneumonectomy.
Institutional characteristics and likelihood of
margin positivity
Surgical procedures performed at institutions desig-
nated as community cancer programs or comprehensive
community cancer programs were more likely to be
associated with positive margins than were those per-
formed at teaching or research institutions or at in-
stitutions designated as National Cancer Institute
programs or networks (see Table 1). Institutions with a
higher proportion of patients with Medicaid or no in-
surance were more likely to have incomplete resections
than were those with the lowest proportion of under-
insured patients. In addition, institutions at which lung
cancer operations constituted a higher percentage of all
surgical procedures and those with higher volumes ofcancer operations in general had signiﬁcantly lower odds
of performing incomplete resections. Sensitivity ana-
lyses, in which we excluded patients with R2 and/or
unspeciﬁed R status, yielded results similar to those of
our primary analyses (Supplementary Table 1).
Pattern of adjuvant therapy use
Radiotherapy was administered to 11,267 patients
(10%) in thewhole cohort and 2335 (43.8%) of thosewith
positive margins, to 206 (8.8%) of whom it was adminis-
tered preoperatively and to 2104 (90.1%) of whom it was
administered postoperatively. Chemotherapy was
administered to 29,845 patients (26.1%) in the whole
cohort. This included 2697 (50.6%) patients with positive
resection margins, in 277 (10.3%) of whom it was used
preoperatively and in 2319 (86%) of whom it was used
postoperatively.
Neoadjuvant therapy and incidence of
incomplete resection
There was a strong association between use of neo-
adjuvant therapy and occurrence of a resection with
positive margins (Table 2). After adjustment for other
factors associated with margin positivity, patients who
received preoperative radiotherapy had a signiﬁcantly
greater likelihood of margin positivity than did those
who did not receive neoadjuvant therapy (adjusted OR ¼
1.59, 95% conﬁdence interval: 1.17–2.15, p ¼ 0.003).
Survival impact of incomplete resection
The crude overall 5-year survival rate of patients with
an R0 resectionwas 58.5% comparedwith 33.8% in those
with positive margins, log-rank p < 0.001, Fig. 2A). This
survival difference persisted when patients were strati-
ﬁed by T category (Fig. 2B), tumor size (Fig. 2C), and
A B
C D
Survival Time in Months Survival Time in Months
Survival Time in MonthsSurvival Time in Months
Figure 2. Kaplan-Meier estimates of 5-year overall survival curves stratiﬁed by margin status: (A) crude; (B) stratiﬁed by T
category; (C) stratiﬁed by tumor size; and (D) stratiﬁed by American Joint Committee on Cancer aggregate tumor node
metastasis stage. M–, patients with resections with negative margins; Mþ, patients with resections with positive margins.
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patients with pT1 disease had a survival curve over-
lapping that of patients with pT3 disease who had an R0
resection (see Fig. 2B). The survival curve of patients
with margin-positive stage I disease overlapped that of
patients with stage II who had an R0 resection. Patients
with incompletely resected stage II disease had a lower
survival rate than did those with completely resected
stage III disease (see Fig. 2D). The survival detriment
was consistent at 1, 3, and 5 years (Supplementary
Table 2).
Sensitivity analyses, in which patients with an R1
resection were analyzed separately from those with
R2 and unspeciﬁed R-status revealed similar results
(Supplementary Table 3). The results were also similarirrespective of whether eligibility was limited to pa-
tients surviving past postoperative day 30, 60, or 90
(Supplementary Table 4).
Survival impact of postoperative adjuvant
therapy in patients with positive margins
The 5-year overall survival of patients with positive
margins varied by stage and treatment modality
(Fig. 3A–C, Table 3). Receipt of chemotherapy was
associated with better survival irrespective of stage.
Radiotherapy was associated with signiﬁcantly lower
survival in patients with stage I disease (log-rank
p < 0.001) but had no signiﬁcant impact on patients
with stage II and III disease. Chemoradiation had no
signiﬁcant impact on patients with stage I disease but
AC
B
Figure 3. Kaplan-Meier estimates of 5-year overall survival of patients with an incomplete lung cancer resection stratiﬁed by
postoperative adjuvant treatment and stage: (A) patients with stage I disease; (B) patients with stage II disease; and (C)
patients with stage III disease.
January 2016 Prevalence, Prognostic Implications, and Survival Modulators e13was associated with improved survival in patients with
stage II and III disease (log-rank p < 0.001). The results
were similar when margin-positive patients with an R1Table 3. Five-year overall survival rates after incomplete lung
treatment
Stage
Five-year overall survival rate
No adjuvant therapy Chemotherapy pa
I 0.49 0.60 0.008
II 0.27 0.35 <0.001
III 0.15 0.25 <0.001
aLog-rank survival comparison with patients in a similar stage but witresection were analyzed separately from those with R2
or unspeciﬁed R status (Supplementary Table 5), and
also when the analysis population excluded patientscancer resection stratiﬁed by stage and postoperative
Radiotherapy pa Chemoradiation pa
0.27 <0.001 0.40 0.34
0.26 0.66 0.34 <0.001
0.10 0.97 0.26 <0.001
hout adjuvant therapy.
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(Supplementary Table 6).
Discussion
The goal of all curative intent surgery in oncology is
to achieve a disease-free plane of tissue at the micro-
scopic margin of resection, thereby increasing assurance
that no disease has been left behind. The adverse sur-
vival impact of resection with positive margins has been
conﬁrmed for many different types of cancer. Indeed, the
rate of resection with positive margins has been pro-
posed as a marker of the quality of rectal cancer care.24
Since at least 2004, the College of American Pathologists
has mandated inclusion of resection margin status in all
pathology reports on lung cancer resection. Tacit
acknowledgment of the negative impact of incomplete
resection of lung cancer has stimulated development of
algorithms for the care of such patients.3
However, the lung cancer literature on the prognostic
implications of margin involvement has been ambiguous.
Some studies suggest a negative impact on sur-
vival,15,16,18,20–22,25–33 whereas others suggest little or no
impact.5,10,17,19,34–36 Furthermore, the role of post-
operative adjuvant therapy in this situation is unclear.
Most reports indicate no beneﬁt from adjuvant radio-
therapy.15–22,30,32 Some reports even recommended it
despite evidence of detrimental effects.20,31 All the pre-
vious reports have been small, single-institution studies
examining from four to 216 cases. Indeed, the cumulative
number of cases in the 28 English-language reports from
1945 to 2010 is approximately 1227.6,10,11,15–22,25–38 Our
8-year NCDB cohort is more than fourfold larger than the
sum of patients in all previous English-language reports.
The size of our cohort has enabled us to deﬁnitively
address several open questions. The reported rate of
margin-positive resection in the existing literature
ranged from 1.2% to 17%.10,38 Our data set, which
represents a heterogeneous group of institutions
covering more than 70% of the U.S. population, estab-
lishes an aggregate annual margin-positive rate
consistently under 6%. In addition, we have identiﬁed
factors associated with the risk for incomplete resec-
tion, quantiﬁed its negative survival impact, and pro-
vided data on the beneﬁt of postoperative adjuvant
therapy in such a situation.
Consistent with previous reports, we found that the
risk for incomplete resection advances with tumor
stage.11,16,21,22,32,38 However, contrary to previous re-
ports, our study shows that resection with positive
margins is not rare in patients with stage I and II non–
small cell lung cancer.16 Such patients represented
35.5% and 36.5% of our cohort, respectively. Also unlike
in previous reports, the negative impact of incomplete
resection on survival was independent of stage.21,22,30Indeed, the impact of incomplete resection was equiva-
lent to at least one level of AJCC stage advancement.
Thus, the survival rate of patients with stage I non-R0
cancer was similar to that of patients with stage II R0
disease, and the survival rate of patients with stage II
non-R0 cancer was worse than that of patients with
stage IIIA R0 disease (see Fig. 2D).
We have clariﬁed that a histologic diagnosis of
squamous cell carcinoma is associated with a higher
risk for incomplete resection than is adenocarcinoma,
which is contrary to certain previous reports.16,38 This
association is probably related to the generally more
proximal location of these tumors. Patients who un-
dergo lobectomy, bilobectomy, or pneumonectomy are
similarly at relatively lower risk than are recipients of
sublobar resection. The association between use of
preoperative adjuvant therapy and incomplete resec-
tion is probably an example of “confounding by indi-
cation.” Patients who are deemed by clinical staging
parameters to be at high risk for incomplete resection
are more likely to be offered preoperative adjuvant
therapy.
We found a strong association between nonclinical
characteristics and the risk for incomplete resection.
Resection margin status appears to be a disparate
outcome of health care for lung cancer that is associated
with patient demographic and institutional characteris-
tics. The speciﬁc patient, institutional, and provider-level
practices driving this association need to be elucidated
to provide a pathway to meaningful quality improve-
ment.39 We can only speculate on the reasons for this
association. One possibility is that certain patients seek
care from less proﬁcient providers with access to fewer
resources. For example, racial minorities seek care from
providers who are less well trained; are less able to
provide high-quality care; and have less access to
high-quality specialists, diagnostic imaging, and
nonemergency care.40 Reducing the negative impact of
incomplete resection requires incidence reduction by
elimination of modiﬁable contributory practices and
postincident risk mitigation.
Irrespective of cancer stage, postoperative adju-
vant chemotherapy is associated with reduced mor-
tality risk after incomplete resection, thus suggesting
the need to consider it for all such patients. However,
a key ﬁnding of this study is that contrary to current
recommendations, postoperative adjuvant radiation
may be profoundly harmful to patients with incom-
pletely resected stage I non–small cell lung cancer.3,11
Clinical trials to conﬁrm these ﬁndings and identify
the best adjuvant therapy options for the different
subsets of patients with an incomplete resection
would be ideal. Such trials will be difﬁcult to conduct,
partly because providers and institutions with access
January 2016 Prevalence, Prognostic Implications, and Survival Modulators e15to large numbers of eligible patients are unlikely to be
actively engaged in clinical trials. However, such a
clinical trial may be a suitable challenge for the Na-
tional Cancer Institute Community Oncology Research
Program.
Our study is limited by the retrospective nature of
the analysis and the unavailability of some important
details about institutional practices (such as intra-
operative use of pathologic examination of frozen sec-
tions). In addition, we lack information on the anatomic
site of margin involvement, the proportion of margin-
positive cases with carcinoma in situ at the margin,
and disease recurrence patterns. Furthermore, whether
the resection was an R1 or R2 resection is unclear in
39% of cases, although our sensitivity analysis suggests
that most of these cases were probably R1 resections.
In any event, our results are consistent even when
the known R1 cases are analyzed separately from the
R2 and unspeciﬁed R cases. Finally, we lack informa-
tion on the criteria for selection of the various adjuvant
therapy options. Nevertheless, the size of the data set
has enabled us to resolve the decades-long debate
about the impact of incomplete lung cancer resection
on survival and provide evidentiary guidance for de-
velopers of clinical management algorithms. Future
work should identify causal links with provider and
institutional practice. The adjuvant therapy options
after incomplete resection of non–small cell lung can-
cer should also be subjected to prospective clinical
trials.
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